Incidence of grade 3-4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis.

Alessandro RizzoVeronica MollicaSara MerlerFranco MorelliGiulia SorgentoniMarco OderdaMatteo SantoniFrancesco Massari

Published in: Expert opinion on drug metabolism & toxicology (2022)

Clinicians should carefully consider these risks, especially taking into account that the use of PARPi in mCRPC patients is expected to rise in the near future.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
dna damage
peritoneal dialysis
risk factors
prognostic factors
risk assessment
combination therapy
current status